- Report
- July 2025
- 150 Pages
United States
From €4383EUR$4,950USD£3,756GBP
- Report
- July 2025
- 150 Pages
Global
From €5269EUR$5,950USD£4,515GBP
- Report
- December 2024
- 100 Pages
Global
From €5269EUR$5,950USD£4,515GBP
- Report
- August 2024
- 120 Pages
Russia
From €5269EUR$5,950USD£4,515GBP
- Report
- August 2025
- 182 Pages
Global
From €3139EUR$3,545USD£2,690GBP
€3488EUR$3,939USD£2,989GBP
- Report
- October 2024
- 200 Pages
Global
From €3321EUR$3,750USD£2,845GBP
- Report
- August 2025
- 197 Pages
Global
From €3139EUR$3,545USD£2,690GBP
€3488EUR$3,939USD£2,989GBP
- Report
- December 2024
- 85 Pages
Spain
From €3099EUR$3,500USD£2,656GBP
- Report
- September 2024
- 80 Pages
France
From €3099EUR$3,500USD£2,656GBP
- Report
- August 2024
- 80 Pages
Japan
From €3099EUR$3,500USD£2,656GBP
- Report
- November 2023
- 30 Pages
Global
From €2435EUR$2,750USD£2,087GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4206EUR$4,750USD£3,604GBP
- Report
- February 2024
- 110 Pages
Global
From €4206EUR$4,750USD£3,604GBP
- Report
- February 2024
- 90 Pages
France
From €4206EUR$4,750USD£3,604GBP
- Report
- July 2025
- 350 Pages
Global
From €4383EUR$4,949USD£3,755GBP
- Report
- June 2023
- 120 Pages
Asia Pacific
From €3426EUR$3,869USD£2,936GBP
- Report
- August 2026
- 70 Pages
Australia
From €4206EUR$4,750USD£3,604GBP
- Report
- February 2024
- 112 Pages
Middle East, Africa
From €4206EUR$4,750USD£3,604GBP
- Report
- December 2024
- 144 Pages
Global
From €13279EUR$14,995USD£11,377GBP
- Report
- October 2020
- 133 Pages
Global
From €13279EUR$14,995USD£11,377GBP

Rapid Acting Insulin is a type of insulin used to treat endocrine and metabolic disorders. It is a short-acting insulin that is injected before meals to help control blood sugar levels. It works quickly to lower blood sugar levels and can be used in combination with other types of insulin. Rapid Acting Insulin is typically used to treat type 1 diabetes, but can also be used to treat type 2 diabetes. It is important to monitor blood sugar levels closely when using Rapid Acting Insulin, as it can cause hypoglycemia if taken in too high of a dose.
Rapid Acting Insulin is available in both injectable and inhaled forms. Injectable forms include regular insulin, lispro, aspart, and glulisine. Inhaled forms include Afrezza and Admelog. These forms of insulin are designed to work quickly and provide a more convenient way to manage blood sugar levels.
Some companies in the Rapid Acting Insulin market include Eli Lilly, Novo Nordisk, Sanofi, and Merck. These companies produce a variety of Rapid Acting Insulin products, including injectable and inhaled forms. Show Less Read more